stoxline Quote Chart Rank Option Currency Glossary
  
AIkido Pharma Inc. (AIKI)
3.56  0.03 (0.85%)    12-22 00:00
Open: 3.55
High: 3.66
Volume: 31,931
  
Pre. Close: 3.53
Low: 3.5
Market Cap: 20(M)
Technical analysis
2023-03-03 4:47:20 PM
Short term     
Mid term     
Targets 6-month :  4.95 1-year :  5.78
Resists First :  4.23 Second :  4.95
Pivot price 3.91
Supports First :  3.81 Second :  3.54
MAs MA(5) :  3.92 MA(20) :  3.91
MA(100) :  4.56 MA(250) :  3.92
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  30.9 D(3) :  42.5
RSI RSI(14): 51.5
52-week High :  7.26 Low :  0.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AIKI ] has closed above bottom band by 47.4%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.92 - 3.95 3.95 - 3.97
Low: 3.7 - 3.72 3.72 - 3.75
Close: 3.86 - 3.9 3.9 - 3.94
Company Description

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Headline News

Thu, 22 Dec 2022
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH) - PR Newswire

Mon, 28 Nov 2022
AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes - BioSpace

Thu, 21 Jul 2022
AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary - PR Newswire

Sun, 12 Jun 2022
AIkido Pharma Appoints Soo Yu Director - citybiz

Fri, 03 Jun 2022
AIkido Announces Reverse Stock Split - PR Newswire

Tue, 05 Apr 2022
AIkido Pharma Announces Strategic Investment in MasterClass - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 4 (M)
Held by Insiders 13.2 (%)
Held by Institutions 10.8 (%)
Shares Short 70 (K)
Shares Short P.Month 75 (K)
Stock Financials
EPS -1.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.92
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -9.2 %
Return on Equity (ttm) -18.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -2.11
PEG Ratio 0
Price to Book value 0.24
Price to Sales 0
Price to Cash Flow -1.99
Stock Dividends
Dividend 1
Forward Dividend 0
Dividend Yield 25.6%
Dividend Pay Date 2019-05-09
Ex-Dividend Date 1980-05-11

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android